Global Rare Dermatological Disease Treatment Market
Global Rare Dermatological Disease Treatment Market

Rare Dermatological Disease Treatment Comprehensive Study by Treatment (Corticosteroids, Immunosuppressants, Anti-inflammatory Agents, Antibiotics, Analgesics, Others), Indication (Systemic Sclerosis (Scleroderma), Epidermolysis Bullosa (EB), Pemphigus Vulgaris, Cutaneous Lupus Erythematosus) Players and Region - Global Market Outlook to 2026

Rare Dermatological Disease Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Sep 2021 Edition 238 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
The skin is the human body's biggest organ. The skin can be affected by a variety of disorders. Some are frequent, while others are uncommon. Eczema or hives, for example, are common skin conditions. Some skin illnesses, on the other hand, afflict significantly fewer people. Many of them are hereditary diseases. Skin disorders are one of the primary sources of non-fatal disease burden around the world. Skin disorders can be caused by ageing, trauma, environmental, and genetic causes. Rare diseases afflict 30 million individuals in the European Union and 25-30 million in the United States, making them a huge public health issue that has yet to be addressed. In the last 50 years, there has been an increase in the incidence and prevalence of systemic sclerosis. Skin illnesses, which are among the most frequent diseases impacting human health, afflict over 900 million people globally at any given moment, according to the World Health Organization (WHO). Pyoderma, scabies, acne, eczema, and warts are some of the most often reported skin disorders in the world.This growth is primarily driven by Increase in Incidence of Rare Diseases and Surge in Research & Development for Orphan Drugs and Rising Incidence of Skin Diseases.

Globally, a noticeable market trend is evident Growing Awareness about Skin Diseases . Major Players, such as Sanofi (France), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Castle Creek Biosciences, Inc. (United States), Merck & Co., Inc. (United States), Bristol-Myers Squibb Company (United States), Pfizer, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Merck KGaA (Germany), Eli Lilly and Company (United States), AbbVie, Inc. (United States), Krystal Biotech, Inc. (United States) and Amryt Pharma plc. (United Kingdom) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On Aug. 25, 2021 - Eli Lilly and Company and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted
In May 2020, Sanofi S.A. had thereby received USFDA approval of Dupixent (dupilumab) for the treatment of moderate to severe atopic dermatitis.

Market Drivers
  • Increase in Incidence of Rare Diseases and Surge in Research & Development for Orphan Drugs
  • Rising Incidence of Skin Diseases

Market Trend
  • Growing Awareness about Skin Diseases
  • Increasing the Demand for This Drug for the Treatment of Mild-To-Moderate Atopic Dermatitis in Children and Adults

Restraints
  • Side Effects Associated With the Drugs and Treatment

Opportunities
Escalating Disposable Income in Developing Countries and Increasing Preference for Consultation with Dermatologists for Chronic Skin Conditions
Challenges
Lack of Access to Skin Care Treatments in the Under Developed Countries

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Rare Dermatological Disease Treatment Study Sheds Light on
— The Rare Dermatological Disease Treatment Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Rare Dermatological Disease Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Rare Dermatological Disease Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Frequently Asked Questions (FAQ):

1. What are the years considered in the Rare Dermatological Disease Treatment Market?
Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026

2. Who are the key players profiled in the Rare Dermatological Disease Treatment Market?
Companies that are profiled in Global Rare Dermatological Disease Treatment Market are Sanofi (France), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Castle Creek Biosciences, Inc. (United States), Merck & Co., Inc. (United States), Bristol-Myers Squibb Company (United States), Pfizer, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Merck KGaA (Germany), Eli Lilly and Company (United States), AbbVie, Inc. (United States), Krystal Biotech, Inc. (United States) and Amryt Pharma plc. (United Kingdom) etc.

3. What is Rare Dermatological Disease Treatment Market?
The skin is the human body's biggest organ. The skin can be affected by a variety of disorders. Some are frequent, while others are uncommon. Eczema or hives, for example, are common skin conditions. Some skin illnesses, on the other hand, afflict significantly fewer people. Many of them are hereditary diseases. Skin disorders are one of the primary sources of non-fatal disease burden around the world. Skin disorders can be caused by ageing, trauma, environmental, and genetic causes. Rare diseases afflict 30 million individuals in the European Union and 25-30 million in the United States, making them a huge public health issue that has yet to be addressed. In the last 50 years, there has been an increase in the incidence and prevalence of systemic sclerosis. Skin illnesses, which are among the most frequent diseases impacting human health, afflict over 900 million people globally at any given moment, according to the World Health Organization (WHO). Pyoderma, scabies, acne, eczema, and warts are some of the most often reported skin disorders in the world.
Report Objectives / Segmentation Covered
By Treatment
  • Corticosteroids
  • Immunosuppressants
  • Anti-inflammatory Agents
  • Antibiotics
  • Analgesics
  • Others

By Indication
  • Systemic Sclerosis (Scleroderma)
  • Epidermolysis Bullosa (EB)
  • Pemphigus Vulgaris
  • Cutaneous Lupus Erythematosus

By Regions
  • South America
    • Brazil
    • Argentina
    • Chile
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Indonesia
    • Thailand
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Spain
    • Sweden
    • Belgium
    • Finland
    • Denmark
    • Russia
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Incidence of Rare Diseases and Surge in Research & Development for Orphan Drugs
      • 3.2.2. Rising Incidence of Skin Diseases
    • 3.3. Market Challenges
      • 3.3.1. Lack of Access to Skin Care Treatments in the Under Developed Countries
    • 3.4. Market Trends
      • 3.4.1. Growing Awareness about Skin Diseases
      • 3.4.2. Increasing the Demand for This Drug for the Treatment of Mild-To-Moderate Atopic Dermatitis in Children and Adults
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Rare Dermatological Disease Treatment, by Treatment, Indication and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Rare Dermatological Disease Treatment (Value)
      • 5.2.1. Global Rare Dermatological Disease Treatment by: Treatment (Value)
        • 5.2.1.1. Corticosteroids
        • 5.2.1.2. Immunosuppressants
        • 5.2.1.3. Anti-inflammatory Agents
        • 5.2.1.4. Antibiotics
        • 5.2.1.5. Analgesics
        • 5.2.1.6. Others
      • 5.2.2. Global Rare Dermatological Disease Treatment by: Indication (Value)
        • 5.2.2.1. Systemic Sclerosis (Scleroderma)
        • 5.2.2.2. Epidermolysis Bullosa (EB)
        • 5.2.2.3. Pemphigus Vulgaris
        • 5.2.2.4. Cutaneous Lupus Erythematosus
      • 5.2.3. Global Rare Dermatological Disease Treatment Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Chile
          • 5.2.3.1.4. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Singapore
          • 5.2.3.2.6. Indonesia
          • 5.2.3.2.7. Thailand
          • 5.2.3.2.8. Australia
          • 5.2.3.2.9. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Spain
          • 5.2.3.3.7. Sweden
          • 5.2.3.3.8. Belgium
          • 5.2.3.3.9. Finland
          • 5.2.3.3.10. Denmark
          • 5.2.3.3.11. Russia
          • 5.2.3.3.12. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Rare Dermatological Disease Treatment (Price)
  • 6. Rare Dermatological Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Castle Creek Biosciences, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co., Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bristol-Myers Squibb Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck KGaA (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Eli Lilly and Company (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. AbbVie, Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Krystal Biotech, Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Amryt Pharma plc. (United Kingdom)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Rare Dermatological Disease Treatment Sale, by Treatment, Indication and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Rare Dermatological Disease Treatment (Value)
      • 7.2.1. Global Rare Dermatological Disease Treatment by: Treatment (Value)
        • 7.2.1.1. Corticosteroids
        • 7.2.1.2. Immunosuppressants
        • 7.2.1.3. Anti-inflammatory Agents
        • 7.2.1.4. Antibiotics
        • 7.2.1.5. Analgesics
        • 7.2.1.6. Others
      • 7.2.2. Global Rare Dermatological Disease Treatment by: Indication (Value)
        • 7.2.2.1. Systemic Sclerosis (Scleroderma)
        • 7.2.2.2. Epidermolysis Bullosa (EB)
        • 7.2.2.3. Pemphigus Vulgaris
        • 7.2.2.4. Cutaneous Lupus Erythematosus
      • 7.2.3. Global Rare Dermatological Disease Treatment Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Chile
          • 7.2.3.1.4. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Singapore
          • 7.2.3.2.6. Indonesia
          • 7.2.3.2.7. Thailand
          • 7.2.3.2.8. Australia
          • 7.2.3.2.9. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Spain
          • 7.2.3.3.7. Sweden
          • 7.2.3.3.8. Belgium
          • 7.2.3.3.9. Finland
          • 7.2.3.3.10. Denmark
          • 7.2.3.3.11. Russia
          • 7.2.3.3.12. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Rare Dermatological Disease Treatment (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Rare Dermatological Disease Treatment: by Treatment(USD Million)
  • Table 2. Rare Dermatological Disease Treatment Corticosteroids , by Region USD Million (2015-2020)
  • Table 3. Rare Dermatological Disease Treatment Immunosuppressants , by Region USD Million (2015-2020)
  • Table 4. Rare Dermatological Disease Treatment Anti-inflammatory Agents , by Region USD Million (2015-2020)
  • Table 5. Rare Dermatological Disease Treatment Antibiotics , by Region USD Million (2015-2020)
  • Table 6. Rare Dermatological Disease Treatment Analgesics , by Region USD Million (2015-2020)
  • Table 7. Rare Dermatological Disease Treatment Others , by Region USD Million (2015-2020)
  • Table 8. Rare Dermatological Disease Treatment: by Indication(USD Million)
  • Table 9. Rare Dermatological Disease Treatment Systemic Sclerosis (Scleroderma) , by Region USD Million (2015-2020)
  • Table 10. Rare Dermatological Disease Treatment Epidermolysis Bullosa (EB) , by Region USD Million (2015-2020)
  • Table 11. Rare Dermatological Disease Treatment Pemphigus Vulgaris , by Region USD Million (2015-2020)
  • Table 12. Rare Dermatological Disease Treatment Cutaneous Lupus Erythematosus , by Region USD Million (2015-2020)
  • Table 13. South America Rare Dermatological Disease Treatment, by Country USD Million (2015-2020)
  • Table 14. South America Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 15. South America Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 16. Brazil Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 17. Brazil Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 18. Argentina Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 19. Argentina Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 20. Chile Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 21. Chile Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 22. Rest of South America Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 23. Rest of South America Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 24. Asia Pacific Rare Dermatological Disease Treatment, by Country USD Million (2015-2020)
  • Table 25. Asia Pacific Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 26. Asia Pacific Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 27. China Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 28. China Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 29. Japan Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 30. Japan Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 31. India Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 32. India Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 33. South Korea Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 34. South Korea Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 35. Singapore Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 36. Singapore Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 37. Indonesia Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 38. Indonesia Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 39. Thailand Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 40. Thailand Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 41. Australia Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 42. Australia Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 43. Rest of Asia-Pacific Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 44. Rest of Asia-Pacific Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 45. Europe Rare Dermatological Disease Treatment, by Country USD Million (2015-2020)
  • Table 46. Europe Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 47. Europe Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 48. Germany Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 49. Germany Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 50. France Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 51. France Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 52. Italy Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 53. Italy Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 54. United Kingdom Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 55. United Kingdom Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 56. Netherlands Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 57. Netherlands Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 58. Spain Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 59. Spain Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 60. Sweden Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 61. Sweden Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 62. Belgium Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 63. Belgium Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 64. Finland Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 65. Finland Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 66. Denmark Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 67. Denmark Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 68. Russia Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 69. Russia Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 70. Rest of Europe Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 71. Rest of Europe Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 72. MEA Rare Dermatological Disease Treatment, by Country USD Million (2015-2020)
  • Table 73. MEA Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 74. MEA Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 75. Middle East Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 76. Middle East Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 77. Africa Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 78. Africa Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 79. North America Rare Dermatological Disease Treatment, by Country USD Million (2015-2020)
  • Table 80. North America Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 81. North America Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 82. United States Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 83. United States Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 84. Canada Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 85. Canada Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 86. Mexico Rare Dermatological Disease Treatment, by Treatment USD Million (2015-2020)
  • Table 87. Mexico Rare Dermatological Disease Treatment, by Indication USD Million (2015-2020)
  • Table 88. Company Basic Information, Sales Area and Its Competitors
  • Table 89. Company Basic Information, Sales Area and Its Competitors
  • Table 90. Company Basic Information, Sales Area and Its Competitors
  • Table 91. Company Basic Information, Sales Area and Its Competitors
  • Table 92. Company Basic Information, Sales Area and Its Competitors
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Rare Dermatological Disease Treatment: by Treatment(USD Million)
  • Table 102. Rare Dermatological Disease Treatment Corticosteroids , by Region USD Million (2021-2026)
  • Table 103. Rare Dermatological Disease Treatment Immunosuppressants , by Region USD Million (2021-2026)
  • Table 104. Rare Dermatological Disease Treatment Anti-inflammatory Agents , by Region USD Million (2021-2026)
  • Table 105. Rare Dermatological Disease Treatment Antibiotics , by Region USD Million (2021-2026)
  • Table 106. Rare Dermatological Disease Treatment Analgesics , by Region USD Million (2021-2026)
  • Table 107. Rare Dermatological Disease Treatment Others , by Region USD Million (2021-2026)
  • Table 108. Rare Dermatological Disease Treatment: by Indication(USD Million)
  • Table 109. Rare Dermatological Disease Treatment Systemic Sclerosis (Scleroderma) , by Region USD Million (2021-2026)
  • Table 110. Rare Dermatological Disease Treatment Epidermolysis Bullosa (EB) , by Region USD Million (2021-2026)
  • Table 111. Rare Dermatological Disease Treatment Pemphigus Vulgaris , by Region USD Million (2021-2026)
  • Table 112. Rare Dermatological Disease Treatment Cutaneous Lupus Erythematosus , by Region USD Million (2021-2026)
  • Table 113. South America Rare Dermatological Disease Treatment, by Country USD Million (2021-2026)
  • Table 114. South America Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 115. South America Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 116. Brazil Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 117. Brazil Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 118. Argentina Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 119. Argentina Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 120. Chile Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 121. Chile Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 122. Rest of South America Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 123. Rest of South America Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 124. Asia Pacific Rare Dermatological Disease Treatment, by Country USD Million (2021-2026)
  • Table 125. Asia Pacific Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 126. Asia Pacific Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 127. China Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 128. China Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 129. Japan Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 130. Japan Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 131. India Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 132. India Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 133. South Korea Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 134. South Korea Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 135. Singapore Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 136. Singapore Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 137. Indonesia Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 138. Indonesia Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 139. Thailand Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 140. Thailand Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 141. Australia Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 142. Australia Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 143. Rest of Asia-Pacific Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 144. Rest of Asia-Pacific Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 145. Europe Rare Dermatological Disease Treatment, by Country USD Million (2021-2026)
  • Table 146. Europe Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 147. Europe Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 148. Germany Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 149. Germany Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 150. France Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 151. France Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 152. Italy Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 153. Italy Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 154. United Kingdom Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 155. United Kingdom Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 156. Netherlands Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 157. Netherlands Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 158. Spain Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 159. Spain Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 160. Sweden Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 161. Sweden Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 162. Belgium Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 163. Belgium Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 164. Finland Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 165. Finland Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 166. Denmark Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 167. Denmark Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 168. Russia Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 169. Russia Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 170. Rest of Europe Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 171. Rest of Europe Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 172. MEA Rare Dermatological Disease Treatment, by Country USD Million (2021-2026)
  • Table 173. MEA Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 174. MEA Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 175. Middle East Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 176. Middle East Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 177. Africa Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 178. Africa Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 179. North America Rare Dermatological Disease Treatment, by Country USD Million (2021-2026)
  • Table 180. North America Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 181. North America Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 182. United States Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 183. United States Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 184. Canada Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 185. Canada Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 186. Mexico Rare Dermatological Disease Treatment, by Treatment USD Million (2021-2026)
  • Table 187. Mexico Rare Dermatological Disease Treatment, by Indication USD Million (2021-2026)
  • Table 188. Research Programs/Design for This Report
  • Table 189. Key Data Information from Secondary Sources
  • Table 190. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Rare Dermatological Disease Treatment: by Treatment USD Million (2015-2020)
  • Figure 5. Global Rare Dermatological Disease Treatment: by Indication USD Million (2015-2020)
  • Figure 6. South America Rare Dermatological Disease Treatment Share (%), by Country
  • Figure 7. Asia Pacific Rare Dermatological Disease Treatment Share (%), by Country
  • Figure 8. Europe Rare Dermatological Disease Treatment Share (%), by Country
  • Figure 9. MEA Rare Dermatological Disease Treatment Share (%), by Country
  • Figure 10. North America Rare Dermatological Disease Treatment Share (%), by Country
  • Figure 11. Global Rare Dermatological Disease Treatment share by Players 2020 (%)
  • Figure 12. Global Rare Dermatological Disease Treatment share by Players (Top 3) 2020(%)
  • Figure 13. Global Rare Dermatological Disease Treatment share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 16. Sanofi (France) Revenue: by Geography 2020
  • Figure 17. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 19. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 21. Castle Creek Biosciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Castle Creek Biosciences, Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 25. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2020
  • Figure 27. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer, Inc. (United States) Revenue: by Geography 2020
  • Figure 29. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 31. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 33. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 34. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 35. AbbVie, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. AbbVie, Inc. (United States) Revenue: by Geography 2020
  • Figure 37. Krystal Biotech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Krystal Biotech, Inc. (United States) Revenue: by Geography 2020
  • Figure 39. Amryt Pharma plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. Amryt Pharma plc. (United Kingdom) Revenue: by Geography 2020
  • Figure 41. Global Rare Dermatological Disease Treatment: by Treatment USD Million (2021-2026)
  • Figure 42. Global Rare Dermatological Disease Treatment: by Indication USD Million (2021-2026)
  • Figure 43. South America Rare Dermatological Disease Treatment Share (%), by Country
  • Figure 44. Asia Pacific Rare Dermatological Disease Treatment Share (%), by Country
  • Figure 45. Europe Rare Dermatological Disease Treatment Share (%), by Country
  • Figure 46. MEA Rare Dermatological Disease Treatment Share (%), by Country
  • Figure 47. North America Rare Dermatological Disease Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Sanofi (France)
  • GlaxoSmithKline plc (United Kingdom)
  • Novartis AG (Switzerland)
  • Castle Creek Biosciences, Inc. (United States)
  • Merck & Co., Inc. (United States)
  • Bristol-Myers Squibb Company (United States)
  • Pfizer, Inc. (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Merck KGaA (Germany)
  • Eli Lilly and Company (United States)
  • AbbVie, Inc. (United States)
  • Krystal Biotech, Inc. (United States)
  • Amryt Pharma plc. (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation